maveropepimut-S (MVP-S) / BioVaxys 
Welcome,         Profile    Billing    Logout  
 19 Diseases   8 Trials   8 Trials   237 News 


12»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), maveropepimut-S (MVP-S) / BioVaxys
    Journal, PD(L)-1 Biomarker, IO biomarker:  Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma. (Pubmed Central) -  Jan 3, 2025   
    High intensity survivin expression is associated with aggressive clinical features supporting a pathobiological role in R/R DLBCL. Future prognostic models incorporating survivin as a clinical biomarker require assessment of intensity, overall expression and should include potential threshold effects of survivin in DLBCL pathobiology.
  • ||||||||||  maveropepimut-S (MVP-S) / BioVaxys
    Trial primary completion date:  Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer (clinicaltrials.gov) -  Jan 25, 2024   
    P1,  N=6, Active, not recruiting, 
    Future prognostic models incorporating survivin as a clinical biomarker require assessment of intensity, overall expression and should include potential threshold effects of survivin in DLBCL pathobiology. Trial primary completion date: Nov 2023 --> Jun 2023
  • ||||||||||  maveropepimut-S (MVP-S) / BioVaxys
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  AVALON: Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) -  Sep 13, 2023   
    P2b,  N=16, Terminated, 
    Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 N=73 --> 16 | Trial completion date: Jun 2026 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Aug 2025 --> Jul 2023; Closure of IMV operations
  • ||||||||||  maveropepimut-S (MVP-S) / BioVaxys
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer (clinicaltrials.gov) -  Aug 14, 2023   
    P1,  N=6, Active, not recruiting, 
    N=73 --> 16 | Trial completion date: Jun 2026 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Aug 2025 --> Jul 2023; Closure of IMV operations Recruiting --> Active, not recruiting | N=18 --> 6 | Trial completion date: Jun 2026 --> Sep 2026 | Trial primary completion date: Jun 2023 --> Sep 2023
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), maveropepimut-S (MVP-S) / BioVaxys
    Trial completion, Checkpoint inhibition:  SPiReL: DPX-Survivac and Checkpoint Inhibitor in DLBCL (clinicaltrials.gov) -  Jul 27, 2023   
    P2,  N=25, Completed, 
    Recruiting --> Active, not recruiting | N=18 --> 6 | Trial completion date: Jun 2026 --> Sep 2026 | Trial primary completion date: Jun 2023 --> Sep 2023 Active, not recruiting --> Completed
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), maveropepimut-S (MVP-S) / BioVaxys
    Trial completion date, Checkpoint inhibition:  SPiReL: DPX-Survivac and Checkpoint Inhibitor in DLBCL (clinicaltrials.gov) -  Nov 10, 2022   
    P2,  N=25, Active, not recruiting, 
    Enrollment has begun. Trial completion date: Oct 2022 --> Oct 2023
  • ||||||||||  maveropepimut-S (MVP-S) / IMV Inc
    DPX-based Immune Education recruits and activates unique subsets of antigen presenting cells to drive immunogenicity of peptide antigens (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_1639;    
    Antigenic peptides formulated in DPX elicit a robust, targeted, and persistent tumor antigen-specific T cell response that for our lead DPX product, Maveropepimut-S, has translated into clinical benefit in multiple cancer indications, including DLBCL and ovarian cancer...Conclusions Collectively these findings highlight quantitative, qualitative, and temporal differences in immune cell recruitment amongst three delivery platforms and show the unique character of the immune response triggered by the DPX platform typified by the recruitment of CD11b + CD11c + APCs that have intrinsically higher capacity for antigen uptake, presentation, and activation. Ethics Approval Experiments were conducted in accordance with ethics protocols approved by the University Committee on Laboratory Animals at Dalhousie University, Halifax, N.S., Canada.
  • ||||||||||  maveropepimut-S (MVP-S) / IMV Inc
    Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy (Exhibit Hall; P1040) -  Apr 8, 2022 - Abstract #IMMUNOLOGY2022IMMUNOLOGY_1423;    
    P1b/2
    Functional annotations of these proteins suggest their role in modulating immune pathways related to Fc receptor mediated signaling and T-cell migration. The results highlight the potential value of plasma exosome assays for monitoring disease and as a potential surrogate response biomarker.
  • ||||||||||  maveropepimut-S (MVP-S) / IMV Inc
    NK cells are involved in promoting anti-tumor responses to DPX-peptide immunotherapy (Section 39) -  Mar 9, 2022 - Abstract #AACR2022AACR_2811;    
    P1b/2
    Maveropepimut-S (MVP-S), formerly DPX-Survivac, contains 5 peptides derived from the tumor antigen survivin, as well as poly dIdC and a T helper peptide...In these mice, DPX-R9F immunization was far less effective than in the Rag1-/- mice, showing that only 20% of immunized mice were tumor free and suggesting that DPX-R9F mediated tumor control was partially dependent upon NK cell/ perforin function. Taken together, these results from both clinical/ translational studies and preclinical models suggest a distinct role for NK cells, in addition to the previously recognized role for T and B cells, in DPX-mediated immunotherapeutic efficacy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), maveropepimut-S (MVP-S) / BioVaxys
    Trial completion date, Trial primary completion date, Checkpoint inhibition:  SPiReL: DPX-Survivac and Checkpoint Inhibitor in DLBCL (clinicaltrials.gov) -  Sep 5, 2021   
    P2,  N=25, Active, not recruiting, 
    Conclusions Collectively, these results provide insight for possible response predictors to MVP-S based therapy Trial Registration NCT02785250 Trial completion date: Apr 2022 --> Oct 2022 | Trial primary completion date: Apr 2021 --> Oct 2021
  • ||||||||||  maveropepimut-S (MVP-S) / BioVaxys
    Trial completion date, Trial primary completion date:  DeCidE1: Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) -  Jun 18, 2021   
    P1b/2,  N=85, Active, not recruiting, 
    N=24 --> 4 | Active, not recruiting --> Terminated; new study Trial completion date: Dec 2020 --> May 2025 | Trial primary completion date: Feb 2020 --> Oct 2020
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), maveropepimut-S (MVP-S) / BioVaxys
    Enrollment closed, Checkpoint inhibition:  SPiReL: DPX-Survivac and Checkpoint Inhibitor in DLBCL (clinicaltrials.gov) -  Feb 15, 2021   
    P2,  N=25, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), maveropepimut-S (MVP-S) / BioVaxys
    Trial completion date, Trial primary completion date, Checkpoint inhibition:  SPiReL: DPX-Survivac and Checkpoint Inhibitor in DLBCL (clinicaltrials.gov) -  Oct 19, 2020   
    P2,  N=25, Recruiting, 
    Enrollment is continuing to further define the patient population most likely to benefit from this well-tolerated therapy. Trial completion date: May 2021 --> Apr 2022 | Trial primary completion date: May 2020 --> Apr 2021